![]() |
![]() |
||||
|
Carol Ammon began her career in 1973 as an associate research scientist at the E.I. du Pont de Nemours and Company in Garden City, New York and by 1996 rose to the position of president of U.S. Pharmaceuticals of DuPont Merck Pharmaceuticals Company. In 1997 she led a management buyout team that purchased 37 pharmaceutical products from DuPont Merck to form Endo Pharmaceuticals. Endo, a specialty pharmaceutical company with market leadership in pain management, became a publicly traded company in July 2000. Based in Chadds Ford, Pennsylvania, Endo also has research facilities in Westbury, New York. Ms. Ammon retired as Chairman of the Board in 2007. Ms. Ammon received the 2003 Greater Philadelphia Ernst & Young Entrepreneur of the Year Award in the Health Sciences category. She was named the CEO of the Year in 2004 by the Eastern Technology Council. In 2005, Ms. Ammon won the Paradigm Award, the Philadelphia region's most prestigious award for businesswomen, and received the Woman of Spirit Award from the Greater Delaware Valley Chapter of the National Multiple Sclerosis Society. Ms. Ammon is chairman of the Christiana Health Care System and a member of the Executive Committee of Christiana Care of Delaware. She is also a member of the Boards of Trustees of Adelphi University, Hagley Museum, and the Delaware Art Museum. Ms. Ammon is also an adjunct professor in the Executive MBA program at the University of Delaware and is a member of Harvard’s Health Advisory Board. Ms. Ammon is a member of the Board of Directors of Pharmacopeia Drug Discovery Inc. in Princeton, N.J. |